Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus OXTRIPHYLLINE PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus OXTRIPHYLLINE PEDIATRIC.
BROVANA vs OXTRIPHYLLINE PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Xanthine derivative that inhibits phosphodiesterase, increasing cyclic AMP levels; antagonizes adenosine receptors, leading to bronchodilation, central nervous system stimulation, and positive inotropic effects.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
200 mg orally every 6-8 hours; extended-release: 400-600 mg orally every 12 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Neonates: 24-36 hours; Infants 1-6 months: 14-29 hours; Children 6-12 months: 9-18 hours; Children 1-9 years: 3-6 hours; Adults: 7-12 hours. Half-life prolonged in hepatic impairment, CHF, and COPD.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal (70-80% as unchanged drug, 10-15% as metabolites); biliary/fecal (<10%)
Category C
Category C
Bronchodilator
Bronchodilator